drugset / Trial / NCT00060567

Dose-Finding Study of E7070 in Combination With Irinotecan

NCT00060567

Phase 1 Completed 88 enrolled Eisai Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

E7070 and irinotecan will be administered to patients with GI tract, pancreatic or lung tumors on Days 1 and 8 of a 21-day cycle, or Days 1 and 15 of a 28-day cycle according to one of two E7070 dose escalation schemes.

Timeline

Start
2003-03
Primary completion
2013-03
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Irinotecan Small molecule 100 mg/m2
Subject Irinotecan Small molecule 125 mg/m2
Subject indisulam Small molecule 250 mg/m2
Subject indisulam Small molecule 400 mg/m2

Indications